PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia

To estimate the cost-effectiveness of sunitinib as first-line treatment for metastatic renal-cell carcinoma (mRCC) from the Colombian health system perspective.

Autores:

Tipo de recurso:

Fecha de publicación:: 2016

Institución:: Universidad del Rosario

Repositorio:: Repositorio EdocUR - U. Rosario

Idioma:: eng

id	EDOCUR2_48a5756409bdca5571f5ec6fc8c8708d
oai_identifier_str	oai:repository.urosario.edu.co:10336/25997
network_acronym_str	EDOCUR2
network_name_str	Repositorio EdocUR - U. Rosario
repository_id_str
spelling	1fa0e86d-4413-430e-9998-a8eacb356a13-1b2ab4121-a073-42e6-94bf-d4a652e599ff-1e6c75e4e-0955-4acd-a862-8fd9a67110a8-1d276bf30-ecf6-417d-b1c6-90f56e3b123a-14ee14d12-6fd9-4eab-94cc-88187323d1f7-12020-08-06T16:20:25Z2020-08-06T16:20:25Z2016-05-01To estimate the cost-effectiveness of sunitinib as first-line treatment for metastatic renal-cell carcinoma (mRCC) from the Colombian health system perspective.application/pdfhttps://doi.org/10.1016/j.jval.2016.03.1586ISSN: 1098-3015EISSN: 1524-4733https://repository.urosario.edu.co/handle/10336/25997engElsevierNo. 3a149 Value in HealthVol. 19Value in Health, ISSN: 1098-3015 ; EISSN: 1524-4733, Vol.19, No.3 (May, 2016); pp.a149https://www.valueinhealthjournal.com/article/S1098-3015(16)01654-5/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301516016545%3Fshowall%3DtrueRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecValue in Healthinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURPublic Health and Health ServicesMedical and Health SciencesApplied EconomicsEconomicsPCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in ColombiaPCN87 Evaluación económica de Sunitinib como tratamiento de primera línea para el carcinoma de células renales metastásico en ColombiaarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Prieto, VAReyes, JMLopez-Cabra, CDiaz, JAUrrego-Novoa10336/25997oai:repository.urosario.edu.co:10336/259972021-06-03 00:50:23.343https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
dc.title.TranslatedTitle.spa.fl_str_mv	PCN87 Evaluación económica de Sunitinib como tratamiento de primera línea para el carcinoma de células renales metastásico en Colombia
title	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
spellingShingle	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia Public Health and Health Services Medical and Health Sciences Applied Economics Economics
title_short	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
title_full	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
title_fullStr	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
title_full_unstemmed	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
title_sort	PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia
dc.subject.keyword.spa.fl_str_mv	Public Health and Health Services Medical and Health Sciences Applied Economics Economics
topic	Public Health and Health Services Medical and Health Sciences Applied Economics Economics
description	To estimate the cost-effectiveness of sunitinib as first-line treatment for metastatic renal-cell carcinoma (mRCC) from the Colombian health system perspective.
publishDate	2016
dc.date.created.spa.fl_str_mv	2016-05-01
dc.date.accessioned.none.fl_str_mv	2020-08-06T16:20:25Z
dc.date.available.none.fl_str_mv	2020-08-06T16:20:25Z
dc.type.eng.fl_str_mv	article
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv	Artículo
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.1016/j.jval.2016.03.1586
dc.identifier.issn.none.fl_str_mv	ISSN: 1098-3015 EISSN: 1524-4733
dc.identifier.uri.none.fl_str_mv	https://repository.urosario.edu.co/handle/10336/25997
url	https://doi.org/10.1016/j.jval.2016.03.1586 https://repository.urosario.edu.co/handle/10336/25997
identifier_str_mv	ISSN: 1098-3015 EISSN: 1524-4733
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.citationIssue.none.fl_str_mv	No. 3
dc.relation.citationStartPage.none.fl_str_mv	a149
dc.relation.citationTitle.none.fl_str_mv	Value in Health
dc.relation.citationVolume.none.fl_str_mv	Vol. 19
dc.relation.ispartof.spa.fl_str_mv	Value in Health, ISSN: 1098-3015 ; EISSN: 1524-4733, Vol.19, No.3 (May, 2016); pp.a149
dc.relation.uri.spa.fl_str_mv	https://www.valueinhealthjournal.com/article/S1098-3015(16)01654-5/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301516016545%3Fshowall%3Dtrue
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv	Restringido (Acceso a grupos específicos)
rights_invalid_str_mv	Restringido (Acceso a grupos específicos) http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Elsevier
dc.source.spa.fl_str_mv	Value in Health
institution	Universidad del Rosario
dc.source.instname.none.fl_str_mv	instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv	reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv	Repositorio institucional EdocUR
repository.mail.fl_str_mv	edocur@urosario.edu.co
_version_	1828160513921515520

PCN87 Economic Evaluation of Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia

Publicaciones similares